

Centre for Global Health Research, Li Ka Shing Knowledge Institute,
Keenan Research Centre, St. Michael's Hospital, University of Toronto

Presents

Denis Xavier MBBS, MD, MSc.

Professor and Head, Pharmacology at St. John's Medical College,
Head of the Division of Clinical Research and Training at
St. John's Research Institute, Bangalore, India.

Brown Bag Presentation

Title: "Innovations in cardiovascular disease prevention through large
Multi-center studies in India."

Tuesday, August 23, 2016
11:30 AM – 12:30 PM
(Coffee will be served)

Introduction by Professor Prabhat Jha
University of Toronto Chair in Disease Control
Director, Centre for Global Health Research

Keenan Research Centre
209 Victoria Street, Toronto ON M5B 1T8
2nd Floor, Room 216

Please see below a short biography.

RSVP to cghr@smh.ca

Short Bio

Prof. Denis Xavier MBBS, MD, MSc (Clin Epi, Canada), Vice-Dean (PG), Professor and Head, Pharmacology at St. John's Medical College, and Head of the Division of Clinical Research and Training at St. John's Research Institute, Bangalore, India.

Together with Prof. Prem Pais he established the Clinical Research Division at St. John's in 1999 and built collaborations in about 200 Centers in India. In over 16 years the collaboration has recruited about 65,000 patients in over 30 projects with plans to recruit over 30,000. The studies include several large **observational studies** and multi-centre **clinical trials** involving anticoagulants, lipid lowering agents, anti-hypertensives, antiplatelet agents, polypills and the impact of non-medical health workers in cardiovascular prevention.

Prof. Xavier was **Principal Investigator** of the National Institutes of Health (NIH, USA) and UH **Center of Excellence** to counter chronic diseases (2009-14) in low and middle income countries. This includes 3 large studies in primary and secondary prevention of cardiovascular disease and a nation-wide stroke registry. He runs courses in Health Research Methods, Biostatistics and Evidence Based Medicine since 7 years. His recent work has expanded to innovative health systems research on heart disease and strokes in low-income settings.

He has published over 90 papers in Journals such as the Lancet, NEJM, JAMA, Circulation, European Heart Journal, Heart, American Heart Journal, Nature Cardiovascular, Indian Heart Journal etc. He reviews for the Lancet, European Heart Journal, American Heart Journal, Translational Medicine and the Journal of Experimental Biology. He also has four book chapters and is presently Section Editor of clinical pharmacology chapters in a cardiology text book.

He is on the **Editorial Board** of the Journal of the American College of Cardiology (JACC), Nature Cardiology and Preventive Cardiology. He also reviews for the Indian Council of Medical Research and for the Drugs Controller General of India. He is the **Chairperson** of the NHA Ethics Committee and a member of the NIMHANS ethics committee.

He has delivered **invited lectures** at Oxford University, UK; McMaster University Canada; Harvard, Stanford, Duke and North Western Universities, USA. Xavier has also delivered invited lectures at the World Congress of Cardiology, Dubai 2012 (2 lectures), Melbourne Australia 2014 (2 lectures), American Heart Association's International Stroke Conference, Los Angeles 2016 (1 lecture).

SELECTED PUBLICATIONS (FROM OVER 95)

1. Yusuf S, Mehta SR, Xie C, Ahmed RJ, **Xavier D**, Pais P, Zhu J, Liu L; CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. **JAMA**. 2005 Jan 26;293(4):427-35. Impact factor: 29.98
2. Karthik G, **Xavier D**, Prabhakar D, Pais P. Perspectives on the management of coronary artery disease in India. **Heart**, November 1, 2007; 93(11): 1334 - 1338. Impact factor: 14.7
3. Deborah Cook, Anne Moore-Cox, **Denis Xavier**, François Lauzier, Ian Roberts, Randomized Trials in Vulnerable Populations. **Clin Trials**2008;5: 61-69.
4. **Denis Xavier**, Prem Pais, PJ Devereaux, Changchun Xie, D Prabhakaran, K Srinath Reddy, Rajeev Gupta, Prashant Joshi, Prafulla Kerkar, S Thanikachalam, KK Haridas, TM Jaison, Sudhir Naik, AK Maity, Salim Yusuf on behalf of the CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. **Lancet**. 2008 Apr 26;371(9622):1435-42.
5. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, **Xavier D**, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. **Lancet**. 2008 May 31;371(9627):1839-47.
6. **Xavier D***, Pais P, Sigamani A, Pogue J, Afzal R, Yusuf S. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. **Nat Clin Pract Cardiovasc Med**. 2008 Dec 23.
7. **Denis Xavier***, PJ Devereaux, Abhinav Goyal, Prem Pais, Salim Yusuf. Polypharmacotherapy for Primary Prevention of Cardiovascular Disease. **Indian Heart J**2008; Suppl B:29–33
8. Yusuf S, Pais P, Afzal R, **Xavier D**, Teo K, Eikelboom J, Sigamani A, et al. Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. **Lancet**. 2009;373:1341-1351
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, **Xavier D**, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. **N Engl J Med**. 2009 Sep 17;361 (12): 1200-2.

10. O'Donnell MJ, **Xavier D**, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusuf K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. **Lancet**. 2010 Jul 10;376(9735):112-23. Epub **2010 Jun 17**. PubMed PMID: 20561675.
11. Lonn E, Bosch J, Teo KK, Pais P, **Xavier D**, Yusuf S. The polypill in the prevention of cardiovascular diseases. Key concepts, current status, challenges, and future directions. **Circulation** **2010**; 122:2078-2088.
12. Gupta R, Guptha S, Joshi R, **Xavier D**. Translating evidence into policy for cardiovascular disease control in India. **Health Res Policy Syst**. **2011 Feb 9**;9:8. PubMed PMID: 21306620; PubMed Central PMCID: PMC3045991.
13. Nerenberg KA, Goyal A, **Xavier D**, Sigamani A, Ng J, Mehta SR, et al. Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit: The RECREATE trial. **Diabetes Care**. **Nov 2011**. Impact Factor: 8.57
14. **Denis Xavier**, Alben Sigamani, Deepak Y. Kamath, Prem Pais. Polypill Is an Important Strategy for the Prevention of Cardiovascular Disease Risk. **Journal of Clinical and Preventive Cardiology**, **April 2012**. Impact Factor: 3.69
15. Devi P, Rao M, Sigamani A, Faruqui A, Jose M, Pais P, **Xavier D** et al. Prevalence, risk factors and awareness of hypertension in India: a systematic review. **J Hum Hypertens** **2012**. IF: 2.69
16. Timothy A. Brighton, John W. Eikelboom, Kristy Mann, Rebecca Mister, Alexander Gallus, Paul Ockelford, Harry Gibbs, Wendy Hague, **Denis Xavier**, Rafael Diaz, Adrienne Kirby, & John Simes Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism, **NEJM** 2012,10.1056/NEJMoa1210384. Impact Factor: 54.42
17. Brighton TA, Eikelboom JW, Mann K, **Xavier D** et al. " Low dose Aspirin for preventing recurrent venous thromboembolism" **New Engl J Med** **2012**; 367: 1979 -1987. Impact Factor: 54.42
18. Yusuf S, Ataran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm J-D, Smith R, Teo K, **Xavier D**. Combination Pharmacotherapy to Prevent CVD: Present Status and Challenges. **Eur Heart J**. **2013**. Impact Factor: 14.723
19. P.J. Devereaux, M. Mrkobrada, D.I. Sessler, K. Leslie, A. Sigamani, **D. Xavier**, S. Yusuf, et al; for the POISE-2 Investigators. Aspirin in Patients Undergoing Noncardiac Surgery. **The New England Journal of Medicine**, **31 March 2014**. PMID: 24679062. Impact Factor: 54.42

20. Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCreedy T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, **Xavier D**. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. **Eur Heart J**. 2014. PMID:24288261. Impact Factor: 14.723
21. Kamath DY, **Xavier D**, Gupta R, Devereaux PJ, Sigamani A, Hussain T, Umesh S, Xavier F, Girish P, George N, Thomas T, Chidambaram N, Joshi R, Pais P, Yusuf S. Rationale and design of a randomized controlled trial evaluating community health worker based interventions for the secondary prevention of acute coronary syndromes in India. **Am Heart J November 2014**; 168: 690-7. Impact Factor: 4.555
22. **Xavier D**, Gupta R, Sigamani A, Kamath DY, Devereaux PJ, George N, Joshi R, Pogue J, Pais P, Yusuf S. Community health worker based intervention for adherence to drugs and lifestyle change after Acute Coronary Syndrome: a pilot randomized controlled trial. **Lancet Diabetes and Endocrinology March 2016**.
23. Gerald S. Bloomfield, **Denis Xavier**, Deshirée Belis , Dewan Alam , Patricia Davis, Prabhakaran Dorairaj, Hassen Ghannem, Robert H. Gilman, Deepak Kamath, Sylvester Kimaiyo, Naomi Levitt, Homero Martinez, Gabriela Mejicano, J. Jaime Miranda, Tracey Perez Koehlmoos, Cristina Rabadán-Diehl, Manuel Ramirez-Zea, Adolfo Rubinstein, Katherine A. Sacksteder, Krisela Steyn, Nikhil Tandon, Rajesh Vedanthan, Tracy Wolbach , Yangfeng Wu, Lijing L. Yan. Training and Capacity Building in LMIC for Research in Heart and Lung Diseases The NHLBI- UnitedHealth Global Health Centers of Excellence Program, **GLOBAL HEART, VOL. 11, NO. 1, 2016 March**.
24. Yusuf S, Bosch J, Dagenais G, Zhu J, **Xavier D**, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez- Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. **N Engl J Med**. 2016 Apr 2
25. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, **Xavier D**, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. **N Engl J Med**. 2016 Apr 2
26. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, **Xavier D**, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S; HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. **N Engl J Med**. 2016 Apr 2